abstract |
PROBLEM TO BE SOLVED: To provide a method for avoiding cleavage of CD16a and defective antibody-dependent cellular cytotoxicity in NK cell activation by cytokines, target cell interaction, and / or tumor infiltration. SOLUTION: A modified version of CD16, a genetically modified cell expressing the modified CD16, and a method involving the genetically modified cell are disclosed. Modified forms of CD16 may exhibit, at least in part, enhanced antitumor and / or antiviral activity due to low sensitivity to ADAM17-mediated shedding upon NK cell stimulation. [Selection diagram] Fig. 2 |